论文部分内容阅读
Background:Hepatocellular carcinoma(HCC) in China frequently occurs in the patients with chronic hepatitis B virus(HBV) infection.Here we present a novel approach(Smart T) of adoptive immunotherapy to prepare multiple tumor antigens activated autologous T lymphocytes ex vivo to treat HBV-related HCC patients.